Potential Theranostics of Cancer Stem Cells, Circulating Tumor Cells (Ctc), and Tumor-Derived Exosomes (EVs) Application in Lung Cancer
A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Cancer Biology".
Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 421
Special Issue Editors
Interests: lung cancer; cancer stem cells; lung tumor microenvironment; miRNAs exosomes; circulating tumor cells (CTC); tumor-derived exosomes (EVs)
Special Issues, Collections and Topics in MDPI journals
Interests: host-tumor interactions; biomarkers; familial cancers; risk factors; germline mutations; tumor invasion front; golorectal cancer; liver metastasis; leukemia
Special Issue Information
Dear Colleagues,
Lung cancer is one of the most common cancers in the world. In 2018, there were over 2 million new cases of lung cancer, and over 1.7 million deaths were attributed to lung cancer. In addition to traditional treatments, targeted therapy has emerged as an important means of disease management for patients with non-small cell lung cancer (NSCLC). In particular, an improvement in NSCLC prognosis has been driven by immunotherapy alone or in combination with chemotherapy in both early and advanced stages, although a fraction of patients are still not responding, with relevant issues in metastatic and, more recently, in early adjuvant settings. In this scenario, cancer stem cells (CSCs), circulating tumor cells (CTCs), and tumor-derived exosomes (EVs) seem to have a central role in tumor development, cancer dissemination, and metastasis and in the resistance to commonly used medical treatments.
This Special Issue is set on the potential theranostics of these subpopulations of cells as future perspectives for more tailored treatments against cancer.
Dr. Beatrice Aramini
Dr. Obul Reddy Bandapalli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer stem cells
- tumor exosomes
- lung cancer
- circulating tumor cells
- theranostics
